NovoCure Competitors and Similar CompaniesClear all

NovoCure's competitors and similar companies include Lyell, Silverback Therapeutics and Zymeworks.

	NovoCure NovoCure is a company engaged in the development, manufacture, and commercialization of solutions for the treatment of solid tumors.	Lyell Lyell Immunopharma is a T-cell reprogramming company to cure patients with solid tumors.	Silverback Therapeutics Silverback Therapeutics is a biotech company developing treatments for cancer, fibrosis, and infectious diseases.	Zymeworks Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics.
Founding Date	Founding Date 2000	Founding Date 2018	Founding Date 2016	Founding Date 2003
Type	Type Public	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech medical devices oncology platform therapy	Tags Healthcare biotech oncology platform therapy	Tags Healthcare biotech oncology therapy	Tags Healthcare biotech oncology therapy
Locations	Locations Saint Helier, JE HQ München, DE Haifa, IL Tokyo, JP Root, CH Malvern, US New York, US see more	Locations South San Francisco, US HQ Bothell, US Seattle, US	Locations Seattle, US HQ	Locations Vancouver, CA HQ Seattle, US
Employees	Employees 1,488	Employees 188	Employees 9067% increase	Employees 45519% increase
Valuation ($)	Valuation ($) 1.8 b	Valuation ($) 243.3 m	Valuation ($) 550.4 m	Valuation ($) 973.3 m
Financial
Revenue (est.)	Revenue (est.) $655.4m (FY, 2025)	Revenue (est.) $36k (FY, 2025)	Revenue (est.) $1.3m (FY, 2022)	Revenue (est.) $106m (FY, 2025)
Net income	Net income ($136.2m) (FY, 2025)	Net income ($274.4m) (FY, 2025)	Net income ($34.7m) (FY, 2022)	Net income ($81.1m) (FY, 2025)
Funding
Total funding raised	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 211m	Total funding raised $ 125.9m